For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251006:nRSF1660Ca&default-theme=true
RNS Number : 1660C Verici Dx PLC 06 October 2025
Verici Dx plc
("Verici Dx" or the "Company")
Update on Tutivia™ test adoption
9 new transplant centres on-boarded
19% increase in ordering clinicians in Q3
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces positive progress in its plans to drive strong
Tutivia™ sales growth following the equity fundraise completed in July.
Commercial scale-up of Tutivia test adoption, a test for acute rejection post
transplant, has progressed in Q3, with a 19% increase in ordering clinicians
in the quarter, and the addition of nine new centres, making a total of 30
transplant centres now onboarded, representing 16% of annual transplants in
the US. Volume growth from this progress is expected from Q4 and the number of
orders in Q3 were consistent with the previous two quarters.
The Company has expanded its commercial team with three new senior sales
hires. In addition, a Director of Clinical Partnerships will be joining the
commercial team in mid-October.
The Board continues to target meeting market expectations for the full year.
Investor presentation
Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial
Officer, will provide a live presentation via the Investor Meet Company
platform on 7 October at 10.00 am BST. This presentation is open to all
existing and potential shareholders. Questions can be submitted at any time
during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet VERICI
DX PLC via:
https://www.investormeetcompany.com/verici-dx-plc/register-investor
(https://www.investormeetcompany.com/verici-dx-plc/register-investor)
Investors who already follow Verici Dx on the Investor Meet Company platform
will automatically be invited.
Verici Dx plc www.vericidx.com (https://vericidx.com/)
Sara Barrington, CEO Via Walbrook PR
Singer Capital Markets (Nominated adviser and Joint Broker) Tel: +44 (0)20 7496 3000
Phil Davies / Sam Butcher
Oberon Capital (Joint Broker) Tel: +44 (0)20 3179 0500
Mike Seabrook / Adam Pollock
Walbrook PR (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
Alice Woodings / Paul McManus Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCBELLBEBLBFBL